18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group

RA Huddart; MJ O'Doherty; A Padhani; GJ Rustin; GM Mead; JK Joffe; P Vasey; SJ Harland; J Loque; G Daugaard; SF Hain; SJ Kirk; JE Mackewn; SP Stenning; Testis Tumour Clinical Study Group NCRI

18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group

RA Huddart, MJ O'Doherty, A Padhani, GJ Rustin, GM Mead, JK Joffe, P Vasey, SJ Harland, J Loque, G Daugaard, SF Hain, SJ Kirk, JE Mackewn, SP Stenning, Testis Tumour Clinical Study Group NCRI

PET Imaging Centre Facility

Research output: Contribution to journal › Article › peer-review

115 Citations (Scopus)

Original language	English
Pages (from-to)	3090 - 3095
Number of pages	6
Journal	Journal of Clinical Oncology
Volume	25
Issue number	21
Publication status	Published - 20 Jul 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Huddart, RA., O'Doherty, MJ., Padhani, A., Rustin, GJ., Mead, GM., Joffe, JK., Vasey, P., Harland, SJ., Loque, J., Daugaard, G., Hain, SF., Kirk, SJ., Mackewn, JE., Stenning, SP., & NCRI, T. T. C. S. G. (2007). 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology, 25(21), 3090 - 3095.

@article{e85e0b32949044f982e49d12c9789a21,

title = "18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group",

author = "RA Huddart and MJ O'Doherty and A Padhani and GJ Rustin and GM Mead and JK Joffe and P Vasey and SJ Harland and J Loque and G Daugaard and SF Hain and SJ Kirk and JE Mackewn and SP Stenning and NCRI, {Testis Tumour Clinical Study Group}",

year = "2007",

month = jul,

day = "20",

language = "English",

volume = "25",

pages = "3090 -- 3095",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "American Society of Clinical Oncology",

number = "21",

}

Huddart, RA, O'Doherty, MJ, Padhani, A, Rustin, GJ, Mead, GM, Joffe, JK, Vasey, P, Harland, SJ, Loque, J, Daugaard, G, Hain, SF, Kirk, SJ, Mackewn, JE, Stenning, SP & NCRI, TTCSG 2007, '18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group', Journal of Clinical Oncology, vol. 25, no. 21, pp. 3090 - 3095.

18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. / Huddart, RA; O'Doherty, MJ; Padhani, A et al.
In: Journal of Clinical Oncology, Vol. 25, No. 21, 20.07.2007, p. 3090 - 3095.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group

AU - Huddart, RA

AU - O'Doherty, MJ

AU - Padhani, A

AU - Rustin, GJ

AU - Mead, GM

AU - Joffe, JK

AU - Vasey, P

AU - Harland, SJ

AU - Loque, J

AU - Daugaard, G

AU - Hain, SF

AU - Kirk, SJ

AU - Mackewn, JE

AU - Stenning, SP

AU - NCRI, Testis Tumour Clinical Study Group

PY - 2007/7/20

Y1 - 2007/7/20

M3 - Article

SN - 1527-7755

VL - 25

SP - 3090

EP - 3095

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 21

ER -

Huddart RA, O'Doherty MJ, Padhani A, Rustin GJ, Mead GM, Joffe JK et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology. 2007 Jul 20;25(21):3090 - 3095.